Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

t assets 9,815 17,575

Property, plant and equipment, net 1,630 1,938

Long-term investments, at fair value 6,043 3,902

Other assets 67 638

Total assets $17,555 $24,053

Liabilities and Stockholders' Deficit

Current liabilities:

Accounts payable $2,648 $2,975

Accrued liabilities 2,588 3,595

Current portion of convertible senior notes,

net of discount 2,482 2,471

Total current liabilities 7,718 9,041

Long-term debt owed to related party 10,000 10,000

Convertible senior notes, net of discount 16,242 16,196

Other liabilities 150 278

Total liabilities 34,110 35,515

Stockholders' deficit:

Common stock 6 6

Additional paid-in capital 228,067 227,895

Accumulated deficit (243,988) (239,142)

Accumulated other comprehensive loss (640) (221)

Total stockholders' deficit (16,555) (11,462)

Total liabilities and stockholders' deficit $17,555 $24,053

(1) The condensed consolidated balance sheet at December 31, 2007, has

been derived from the audited consolidated financial statements at

that date included in the Company's Annual Report on Form 10-K for the

fiscal year ended December 31, 2007.

Vermillion, Inc. a
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... Nov. 14 Techne Corporation,(Nasdaq: TECH ) today ... of up to $150 million of the Company,s outstanding ... an expiration date.,The manner of purchases, the amount that ... purchases will be at the discretion of management,and will ...
... Shipments to Fill Backlog of Orders, JACKSONVILLE, Fla., ... PHLC) (the "Company") announced today that,its has recently produced ... sale of the product in 450 7-Eleven stores located,from ... recently completed a production of its new, larger (20-oz.),version ...
... Hollingsworth & Vose,Company (H&V), a leading global ... its HVision(TM) technology platform, a collaborative,process designed ... products. "HVision will provide H&V with ... new generation of products that exceed present ...
Cached Biology Technology:Techne Corporation Announces Share Repurchase Authorization 2Phlo Affiliate Ships Product to Launch 450 7-Eleven Stores 2H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products 2
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Therapeutics, Inc., reversed the growth of lung tumors in mice ... reveals that a tiny bit of RNA may one day ... for future patients battling one of the most prevalent and ... has shown a positive effect of microRNAs in shrinking lung ...
... into venom produced by snakes and spiders, venomous fish ... Now, a study of 158 catfish species, published in ... has catalogued the presence of venom glands and investigated ... the University of Michigan, USA, carried out the investigation. ...
... Kew and the Natural History Museum believe that carnivorous behaviour ... many commonly grown plants such as petunias at ... Murderous plants: Victorian Gothic, Darwin and modern insights into vegetable ... Botanical Journal of the Linnean Society . Carnivorous plants ...
Cached Biology News:Scientists think 'killer petunias' should join the ranks of carnivorous plants 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Biology Products: